Literature DB >> 9557613

V-myc in a simple, single gene retroviral vector causes rapid induction of leukemia and concomitant apoptosis following bone marrow transplantation.

A Dolnikov1, Y Shounan, M Millington, K Mackenzie, G Symonds.   

Abstract

We have previously developed an in vivo model of leukemogenesis utilizing mice reconstituted with genetically modified bone marrow cells. Based on those studies, a new single gene retroviral vector has been engineered which efficiently transfers v-myc into immature murine bone marrow cells. All reconstituted mice developed leukemia with a short latency period (5-11 weeks). In addition to hyperproliferation associated with elevated levels of PCNA, extensive apoptosis was also observed in all leukemic animals with p53 accumulating in the apoptotic cells. Whereas bax encoded protein, an effector of p53 apoptotic activity was detected in apoptotic cells, p21Waf1 protein, a potential mediator of p53 growth suppression was not detected in these cells suggesting that v-myc-induced apoptosis was independent of the ability of p53 to induce p21Waf1. These results indicate that apoptosis, a part of the cellular response to v-myc expression, does not prevent leukemia development and that hyperproliferation rather than abrogation of oncogene-induced apoptosis appears to be a critical event in v-myc-induced leukemia.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9557613     DOI: 10.1038/sj.leu.2400968

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  2 in total

1.  GSK-3β inhibition promotes early engraftment of ex vivo-expanded haematopoietic stem cells.

Authors:  A Dolnikov; N Xu; S Shen; E Song; T Holmes; G Klamer; T A O'Brien
Journal:  Cell Prolif       Date:  2014-02-12       Impact factor: 6.831

2.  Inhibition of the intrinsic but not the extrinsic apoptosis pathway accelerates and drives MYC-driven tumorigenesis towards acute myeloid leukemia.

Authors:  Kari Högstrand; Eduar Hejll; Birgitta Sander; Björn Rozell; Lars-Gunnar Larsson; Alf Grandien
Journal:  PLoS One       Date:  2012-02-29       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.